Dimitra Dafou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9177835/publications.pdf

Version: 2024-02-01

43 papers

2,706 citations

257450

24

h-index

254184 43 g-index

43 all docs 43 docs citations

43 times ranked

6359 citing authors

#	Article	IF	CITATIONS
1	UBE2T promotes β atenin nuclear translocation in hepatocellular carcinoma through MAPK/ERKâ€dependent activation. Molecular Oncology, 2022, 16, 1694-1713.	4.6	11
2	A Systematic Review of Common and Brain-Disease-Specific RNA Editing Alterations Providing Novel Insights into Neurological and Neurodegenerative Disease Manifestations. Biomolecules, 2022, 12, 465.	4.0	9
3	Carnosic Acid and Carnosol Display Antioxidant and Anti-Prion Properties in In Vitro and Cell-Free Models of Prion Diseases. Antioxidants, 2022, 11, 726.	5.1	9
4	Association of Matrix Metalloproteinase (MMP) Gene Polymorphisms With Knee Osteoarthritis: A Review of the Literature. Cureus, 2021, 13, e18607.	0.5	10
5	Validation of Poly(Propylene Imine) Glycodendrimers Towards Their Anti-prion Conversion Efficiency. Molecular Neurobiology, 2020, 57, 1863-1874.	4.0	14
6	Application of antibody phage display to identify potential antigenic neural precursor cell proteins. Journal of Biological Research, 2020, 27, 14.	2.1	2
7	The Tumor Suppressor CYLD Inhibits Mammary Epithelial to Mesenchymal Transition by the Coordinated Inhibition of YAP/TAZ and TGF \hat{I}^2 Signaling. Cancers, 2020, 12, 2047.	3.7	10
8	RNA editing alterations define manifestation of prion diseases. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 19727-19735.	7.1	17
9	Cerebrospinal fluid neurofilament light in suspected sporadic Creutzfeldt-Jakob disease. Journal of Clinical Neuroscience, 2019, 60, 124-127.	1.5	18
10	MicroRNA Alterations in the Brain and Body Fluids of Humans and Animal Prion Disease Models: Current Status and Perspectives. Frontiers in Aging Neuroscience, 2018, 10, 220.	3.4	18
11	Regional and subtype-dependent miRNA signatures in sporadic Creutzfeldt-Jakob disease are accompanied by alterations in miRNA silencing machinery and biogenesis. PLoS Pathogens, 2018, 14, e1006802.	4.7	26
12	Down-regulation of the Tumor Suppressor CYLD Enhances the Transformed Phenotype of Human Breast Cancer Cells. Anticancer Research, 2017, 37, 3493-3503.	1.1	11
13	Hepatitis C virus suppresses Hepatocyte Nuclear Factor 4 alpha, a key regulator of hepatocellular carcinoma. International Journal of Biochemistry and Cell Biology, 2016, 78, 315-326.	2.8	12
14	Induced Pluripotent Stem Cell Differentiation and Three-Dimensional Tissue Formation Attenuate Clonal Epigenetic Differences in Trichohyalin. Stem Cells and Development, 2016, 25, 1366-1375.	2.1	10
15	Mutations in GRHL2 Result in an Autosomal-Recessive Ectodermal Dysplasia Syndrome. American Journal of Human Genetics, 2014, 95, 308-314.	6.2	48
16	The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility. Science Signaling, 2014, 7, ra78.	3.6	34
17	Pregnancyâ€associated plasma protein A regulates mitosis and is epigenetically silenced in breast cancer. Journal of Pathology, 2014, 233, 344-356.	4.5	27
18	3D InÂVitro Model of a Functional Epidermal Permeability Barrier from Human Embryonic Stem Cells and Induced Pluripotent Stem Cells. Stem Cell Reports, 2014, 2, 675-689.	4.8	97

#	Article	IF	Citations
19	De Novo Mutations in MLL Cause Wiedemann-Steiner Syndrome. American Journal of Human Genetics, 2012, 91, 358-364.	6.2	225
20	Mutations in the \hat{I}^3 -Secretase Genes NCSTN , PSENEN , and PSEN1 Underlie Rare Forms of Hidradenitis Suppurativa (Acne Inversa). Journal of Investigative Dermatology, 2012, 132, 2459-2461.	0.7	126
21	De Novo Mutations of the Gene Encoding the Histone Acetyltransferase KAT6B Cause Genitopatellar Syndrome. American Journal of Human Genetics, 2012, 90, 290-294.	6.2	86
22	Mutations in NOTCH2 cause Hajdu-Cheney syndrome, a disorder of severe and progressive bone loss. Nature Genetics, 2011, 43, 303-305.	21.4	291
23	TNF gene cluster deletion abolishes lipopolysaccharide-mediated sensitization of the neonatal brain to hypoxic ischemic insult. Laboratory Investigation, 2011, 91, 328-341.	3.7	48
24	Gain-of-Function Mutations of ARHGAP31, a Cdc42/Rac1 GTPase Regulator, Cause Syndromic Cutis Aplasia and Limb Anomalies. American Journal of Human Genetics, 2011, 88, 574-585.	6.2	100
25	Dymeclin, the gene underlying Dyggve-Melchior-Clausen syndrome, encodes a protein integral to extracellular matrix and golgi organization and is associated with protein secretion pathways critical in bone development. Human Mutation, 2011, 32, 231-239.	2.5	26
26	Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. International Journal of Cancer, 2011, 128, 2063-2074.	5.1	54
27	Profiling signatures of ovarian cancer tumour suppression using 2D-DIGE and 2D-LC-MS/MS with tandem mass tagging. Journal of Proteomics, 2011, 74, 451-465.	2.4	28
28	Modelling genetic and clinical heterogeneity in epithelial ovarian cancers. Carcinogenesis, 2011, 32, 1540-1549.	2.8	36
29	Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nature Genetics, 2011, 43, 929-931.	21.4	440
30	Novel SPG11 mutations in Asian kindreds and disruption of spatacsin function in the zebrafish. Neurogenetics, 2010, 11, 379-389.	1.4	26
31	Cancer Stem Cells and Epithelial Ovarian Cancer. Journal of Oncology, 2010, 2010, 1-9.	1.3	30
32	Senescent Fibroblasts Promote Neoplastic Transformation of Partially Transformed Ovarian Epithelial Cells in a Three-dimensional Model of Early Stage Ovarian Cancer. Neoplasia, 2010, 12, 317-IN3.	5.3	78
33	Microcell-Mediated Chromosome Transfer Identifies EPB41L3 as a Functional Suppressor of Epithelial Ovarian Cancers. Neoplasia, 2010, 12, 579-IN18.	5.3	38
34	Species and Strain Glycosylation Patterns of PrPSc. PLoS ONE, 2009, 4, e5633.	2.5	12
35	Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival. Human Molecular Genetics, 2009, 18, 1869-1878.	2.9	17
36	Chromosomes 6 and 18 induce neoplastic suppression in epithelial ovarian cancer cells. International Journal of Cancer, 2009, 124, 1037-1044.	5.1	11

DIMITRA DAFOU

#	Article	IF	CITATIONS
37	Threeâ€dimensional <i>inÂvitro</i> cell biology models of ovarian and endometrial cancer. Cell Proliferation, 2009, 42, 219-228.	5.3	60
38	<i>In vitro</i> threeâ€dimensional modelling of human ovarian surface epithelial cells. Cell Proliferation, 2009, 42, 385-393.	5.3	46
39	Design and validation of a high-throughput assay to detect codon 146 polymorphisms in the caprine prion protein gene. Analytical Biochemistry, 2009, 393, 229-233.	2.4	1
40	Evaluation of the Possible Transmission of BSE and Scrapie to Gilthead Sea Bream (Sparus aurata). PLoS ONE, 2009, 4, e6175.	2.5	19
41	<i>FBXW7/hCDC4</i> Is a General Tumor Suppressor in Human Cancer. Cancer Research, 2007, 67, 9006-9012.	0.9	458
42	Human ovarian surface epithelial cells immortalized with hTERT maintain functional pRb and p53 expression. Cell Proliferation, 2007, 40, 780-794.	5. 3	37
43	A modified medium that significantly improves the growth of human normal ovarian surface epithelial (OSE) cells in vitro. Laboratory Investigation, 2004, 84, 923-931.	3.7	30